Amman Bradford K. 4
4 · Vivos Therapeutics, Inc. · Filed Nov 27, 2024
Insider Transaction Report
Form 4
Amman Bradford K.
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2024-11-26$2.64/sh+149,533$394,767→ 180,533 totalExercise: $2.64Exp: 2034-09-07→ Common Stock (149,533 underlying)
Holdings
- 80
Common Stock
Footnotes (1)
- [F1]On September 7, 2024 (the "Grant Date"), the Reporting Person received a grant of 180,533 stock options, which grant was made under but subject to stockholder approval of the Issuer's 2024 Omnibus Equity Incentive Plan and such grant at the Issuer's 2024 Annual Meeting. Such meeting was held, and such stockholder approval was obtained, on November 26, 2024. Stock options shall vest and become exercisable in three installments subject to achievement of the following three performance metrics: (1) quarter over quarter revenue growth of at least 15% over the same prior year quarter, (2) total stockholder return from date of grant, and (3) positive cash flow for two consecutive quarters.